Pipeline

SCROLL



GAlA Platform

RN0361

Preclinical IND-Enabling Ph1 Ph2 Ph3

Hypertriglyceridemia ApoC3

RN3161

Preclinical IND-Enabling Ph1 Ph2 Ph3

Obesity INHBE

RN5681

Preclinical IND-Enabling Ph1 Ph2 Ph3

ASCVD PCSK9-Lp(a)

RN0191

Preclinical IND-Enabling Ph1 Ph2 Ph3

Hypercholesterolemia PCSK9

RN1871

Preclinical IND-Enabling Ph1 Ph2 Ph3

Hypertension AGT

RN3271

Preclinical IND-Enabling Ph1 Ph2 Ph3

Cardiomyopathy TTR

RNK288

Preclinical IND-Enabling Ph1 Ph2 Ph3

IgAN Undisclosed

RNN798

Preclinical IND-Enabling Ph1 Ph2 Ph3

MASH, Hyperlipidemia CIDEB

RN679

Preclinical IND-Enabling Ph1 Ph2 Ph3

Metabolic Syndrome Undisclosed

RN609

Preclinical IND-Enabling Ph1 Ph2 Ph3

Metabolic Syndrome Undisclosed

APOLLO Platform

RN596

Preclinical IND-Enabling Ph1 Ph2 Ph3

Obesity Undisclosed

RN508

Preclinical IND-Enabling Ph1 Ph2 Ph3

Obesity Undisclosed

RN517

Preclinical IND-Enabling Ph1 Ph2 Ph3

Metabolic Diseases Undisclosed

RN201

Preclinical IND-Enabling Ph1 Ph2 Ph3

Epilepsy Undisclosed

RN276

Preclinical IND-Enabling Ph1 Ph2 Ph3

Alzheimer's Disease Tau(Cross BBB)

PLATTFORM



Jinyu Huang, Ph.D.

Chief Executive Officer, Founder

Stella Shi is founder, Chief Executive Officer and chairs the board of Rona Therapeutics since company inception in 2021 bringing ~15 years of biopharmaceutical industry and venture capital experience. Prior to founding Rona Therapeutics, Stella was managing director in Lilly Asia Ventures (LAV) from 2015 with proven track records with various venture creation ...